Current Report Filing (8-k)
May 18 2017 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2017
Recro Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
|
|
001-36329
|
|
26-1523233
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
490 Lapp Road, Malvern, Pennsylvania
|
|
19355
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (484) 395-2470
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
On May 12, 2017, Recro
Pharma, Inc. (the
Company
) held its 2017 Annual Meeting of Shareholders (the
Annual Meeting
). The following is a brief description of the final voting results for each of the proposals submitted to a vote of the
shareholders at the Annual Meeting.
(a)
|
Proposal 1 Election of Class III Directors.
Each of Alfred Altomari, William L. Ashton and Dr. Michael Berelowitz were elected to the Board of Directors as Class III directors to serve until the
Companys 2020 annual meeting of shareholders, as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Votes For
|
|
Votes Withheld
|
|
|
Broker Non-Votes
|
|
Alfred Altomari
|
|
13,157,405
|
|
|
508,828
|
|
|
|
2,818,253
|
|
William L. Ashton
|
|
13,628,626
|
|
|
37,607
|
|
|
|
2,818,253
|
|
Dr. Michael Berelowitz
|
|
13,628,426
|
|
|
37,807
|
|
|
|
2,818,253
|
|
(b)
|
Proposal 2 Ratification of Independent Registered Public Accountants.
The appointment of KPMG LLP as the Companys independent registered public accounting firm for the 2017 fiscal year was ratified,
as follows:
|
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
16,364,163
|
|
117,164
|
|
3,159
|
|
0
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
Recro Pharma, Inc.
|
|
|
By:
|
|
/s/ Gerri A. Henwood
|
Name:
|
|
Gerri A. Henwood
|
Title:
|
|
Chief Executive Officer
|
Date: May 18, 2017
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Sep 2023 to Sep 2024